Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus-Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation.

ABSTRACT:

SUBMITTER: Ainley L 

PROVIDER: S-EPMC7783564 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature